{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DLT will be defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-500 as a SA or in combination with pembrolizumab. Toxicity will be evaluated according to NCI CTCAE version 5.0.","groups":[{"description":"Participants were planned to receive TAK-500 at recommended doses based on dose escalation cohorts. No participants were enrolled in the expansion phase due to early termination of the study before initiating this phase.","id":"OG000","title":"Dose Expansion: TAK-500"}],"populationDescription":"Due to early study termination, Dose Expansion Phase was not initiated and hence, no data was collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 32.8 months","title":"Dose Expansion: Number of Participants With Dose Limiting Toxicities (DLTs)","type":"SECONDARY"}